First US clinical trial testing efficacy of delivering aerosolized chemotherapy
City of Hope is recruiting patients with gastric cancer for a trial of a chemotherapy spray that can be delivered straight to... Read More
Immune Protein IL-17A Responsible for Lethal Side Effects of Gastric Cancer
Researchers in Japan discovered that the pro-inflammatory cytokine IL-17A plays a role in promoting peritoneal spread in gastric cancer, and they suggested... Read More
Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
Effect of Lifestyle Factors and Garlic Supplementation on Gastric Cancer Incidence
A study of more than 3,000 people found that those who took garlic supplements regularly were protected from gastric cancer, provided they... Read More
Epstein-Barr virus rewires host epigenomes to drive stomach cancer
Epstein-Barr virus is known to raise the risk of gastric cancer. A recent study explains how the virus “rewires” the epigenome to... Read More
Fluctuating expression of miR-584 in primary and high-grade gastric cancer
A recent study found that H. Pylori infection raises levels of a particular miRNA, which could be used as a biomarker for... Read More
Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Harvard researchers found that people with a history of dental problems also face an increased risk of esophageal and gastric cancer.
Nivolumab Demonstrates Efficacy in Preliminary Data for Gastric Cancer
Gastric cancer patients taking the immune-boosting drug Opdivo in a clinical trial had a disease control rate of 39%, according to a... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
Drug-Drug Interactions to Avoid in Patients With GI Cancer
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.